RAC-UN — Rithm Acquisition Corp.

Rite Aid Corporation (RAC-UN) Q1 2024 Earnings Call Summary

1. Key Financial Results and Metrics:

• Adjusted EBITDA: $91.7 million, down from $100.1 million year-over-year.
• Net Loss: $306.7 million ($5.56 per share), with an adjusted net loss of $40.1 million ($0.73 per share).
• Impairment Charge: $152 million related to goodwill at Elixir.
• Retail Pharmacy Revenue: Increased 3.4% year-over-year, driven by acute and maintenance prescriptions.
• Same Store Sales: Increased 8.4%, with pharmacy sales up 13.3% but front-end sales down 4.4%.
• Script Growth: Increased by 4.7%, or 7.4% excluding COVID-related impacts.

2. Strategic Updates and Business Highlights:

• Pharmacy Initiatives: Focus on adherence programs resulted in a 10.3% increase in courtesy refills and plans to roll out a program to reduce abandoned scripts.
• Front-End Sales Strategy: Launched Ryshi, a new line of beauty and personal care products, with plans for 208 new items this year.
• Elixir Insurance: Decision to exit the individual Medicare Part D market effective January 2024 due to adverse selection and unfavorable utilization trends.
• Cost Control: Retail SG&A improved by $4.8 million due to transformation initiatives and store closures.

3. Forward Guidance and Outlook:

• Adjusted EBITDA Guidance: Expected to be between $90 million and $100 million for Elixir; Retail EBITDA remains at $240 million to $260 million.
• Total Revenue Guidance: Revised to $22.6 billion to $23 billion, reflecting increased sales volume in high-dollar GLP-1s.
• Capital Expenditure: Reduced guidance to $175 million.
• Cash Flow: Anticipated cash use of $100 million to $150 million in fiscal 2024, with sufficient liquidity expected throughout the year.

4. Bad News, Challenges, or Points of Concern:

• Higher Medical Loss Ratio: Elixir's medical loss ratio is trending higher than expected, impacting profitability.
• Front-End Sales Decline: Comp store transactions down 7.9%, attributed to reduced demand for respiratory products and supply chain challenges.
• Shrink Issues: Increased shrink costs, which were $9 million higher than the previous year, continue to be a significant concern.
• Competitive Pressures: Ongoing challenges in the retail pharmacy market, particularly regarding consumer behavior and competition.

5. Notable Q&A Insights:

• COVID Vaccine Impact: Significant drop in COVID vaccine administration, with only 500,000 vaccines given compared to 1.7 million last year.
• Kroger Dispute: No specific quantification of impact yet, but management is optimistic about capturing fair share of volume.
• Individual Medicare Part D Exit: Approximately 300,000 lives affected, with minimal profitability from this segment.
• Debt and Capital Structure: Ongoing discussions with lenders regarding 2025 debt maturities, with no specific updates provided.
• Shrink Management: New leadership hired in loss prevention to address shrink challenges, with innovative strategies expected.

This summary encapsulates the key points from Rite Aid's Q1 2024 earnings call, highlighting both the progress and challenges faced by the company as it navigates its turnaround strategy.